Minimally invasive surfactant therapy versus InSurE in preterm neonates of 28 to 34 weeks with respiratory distress syndrome on non-invasive positive pressure ventilation —a randomized controlled trial

Conclusion: There is no difference between MIST and InSurE in preterm neonates with RDS with NIPPV as a primary mode of respiratory support. Larger multicentre studies are needed to further explore differences in treatment failure and other secondary outcomes.Trial registration:www.ctri.nic.in id CTRI/2019/03/017992, registration date March 8, 2019.What is Known• InSurE is commonly used for many years for treatment of RDS in preterm neonates.• MIST has been introduced as a newer tool.What is New• MIST with feeding tube is comparable with InSurE in preterm infants with RDS in developing countries.•NIPPV can be used as primary respiratory support for MIST.
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research